Sangamo Therapeutics (SGMO) Tops Q3 EPS by 10c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. MSFT
4. META
5. PLTR
6. CSCO
7. KTOS
8. LDOS
9. LBRX
10. BMY

Go back to Sangamo Therapeutics (SGMO) Tops Q3 EPS by 10c, Revenues Beat

Sangamo Therapeutics Reports Third Quarter 2019 Financial Results

November 6, 2019 4:02 PM EST

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported third quarter 2019 financial results and recent business highlights.

We continue to prioritize and progress our clinical development programs, as demonstrated by the accepted ASH poster presentations for our two most advanced programs, SB-525 hemophilia A gene therapy and ST-400 beta thalassemia cell therapy. Patients are currently being screened for enrollment into the clinical study evaluating ST-920, our wholly... More